Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Clinical trial NCT07060001 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07060001
Sponsor: The Methodist Hospital Research Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)

Start date: 2026-04-01
Primary completion: 2028-12-01
Enrollment: 112

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.